Cited 7 times since 2016 (0.8 per year) source: EuropePMC Pharmacogenomics, Volume 17, Issue 15, 20 3 2016, Pages 1621-1628 Rooted in risk: genetic predisposition for low-density lipoprotein cholesterol level associates with diminished low-density lipoprotein cholesterol response to statin treatment. Smit RA, Postmus I, Trompet S, Barnes MR, Warren H, Arsenault BJ, Chasman DI, Cupples LA, Hitman GA, Krauss RM, Li X, Psaty BM, Stein CM, Rotter JI, Jukema JW
Aims
To utilize previously reported lead SNPs for low-density lipoprotein cholesterol (LDL-c) levels to find additional loci of importance to statin response, and examine whether genetic predisposition to LDL-c levels associates with differential statin response.
Methods
We investigated effects on statin response of 59 LDL-c SNPs, by combining summary level statistics from the Global Lipids Genetics and Genomic Investigation of Statin Therapy consortia.
Results
Lead SNPs for APOE, SORT1 and NPC1L1 were associated with a decreased LDL-c response to statin treatment, as was overall genetic predisposition for increased LDL-c levels as quantified with 59 SNPs, with a 5.4% smaller statin response per standard deviation increase in genetically raised LDL-c levels.
Conclusion
Genetic predisposition for increased LDL-c level may decrease efficacy of statin therapy.
